PRT13722

September 10, 2026: Prelude Therapeutics (NASDAQ: PRLD) said the FDA cleared its IND for PRT13722, an oral selective KAT6A degrader, allowing a Phase 1 trial to proceed in HR-positive/HER2-negative breast cancer. The company expects to begin patient enrollment in Q4 2026.

The first-in-human, open-label, multicenter Phase 1 study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of PRT13722 as both monotherapy and in combination with endocrine and targeted therapies in adults with locally advanced or metastatic HR+/HER2- breast cancer.

Prelude described PRT13722 as a highly potent, selective, orally bioavailable KAT6A degrader and said its strategy is to degrade KAT6A while sparing KAT6B, with the goal of improving efficacy, tolerability, and combinability versus dual KAT6A/B inhibitors. No clinical efficacy data were reported in this release.